Agilent Technologies Inc

NYSE A

Data sourced from

and

Download Data

Agilent Technologies Inc Research and Development (R&D) Expenses 1 year YoY Change (%) for the year ending October 31, 2023: 3.00%

Agilent Technologies Inc Research and Development (R&D) Expenses 1 year YoY Change (%) is 3.00% for the year ending October 31, 2023, a -49.15% change year over year. Research and Development (R&D) Expenses consist of the costs associated with the development of new products, technologies, or improvements to existing products. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Agilent Technologies Inc Research and Development (R&D) Expenses for the year ending October 31, 2022 was USD 467.00 M, a 5.90% change year over year.
Agilent Technologies Inc Research and Development (R&D) Expenses for the year ending October 31, 2021 was USD 441.00 M, a -10.91% change year over year.
Agilent Technologies Inc Research and Development (R&D) Expenses for the year ending October 31, 2020 was USD 495.00 M, a 22.52% change year over year.
Agilent Technologies Inc Research and Development (R&D) Expenses for the year ending October 31, 2019 was USD 404.00 M, a 4.94% change year over year.

NYSE: A

Agilent Technologies Inc

CEO	Mr. Michael R. McMullen
IPO Date	Nov. 18, 1999
Location	United States
Headquarters	5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051
Employees	18,000
Sector	Healthcare
Industry	Diagnostics & research

Description

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment focuses on genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and offers services portfolio, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Key trends